103939BioEP: Proof of ConceptClosedCollaborative R&DInnovate UKEpilepsy is a serious neurological condition that affects almost 1% of the population at some stage in their lives. It is a condition with high economic (£15bn annually across Europe) and social (>1000 deaths annually in the UK) costs. In this project, Neuronostics seeks to demonstrate proof of concept for its lead product, BioEP. BioEP is a novel precision medicine tool that can identify whether or not someone has epilepsy and whether or not they are responding to treatment. In contrast to current clinical practice, which can only answer these questions if seizures occur whilst being monitored clinically, BioEP uses advanced mathematical and computational algorithms to interrogate the electrical activity of the brain and reveal susceptibility to epilepsy. BioEP additionally offers the potential to determine whether or not someone is responding effectively to treatment. For the millions of people with epilepsy worldwide BioEP offers the opportunity for fast, effective and objective clinical decision making.